Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of SHR-A1811 with or without pertuzumab versus trastuzumab + pertuzumab + docetaxel in HER2-positive recurrent or metastatic breast cancer
CTR20232893Phase 3Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Nov 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab rezetecan in breast cancer, sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Nov 2023; status: active.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20232893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232893.